• The U.S. FDA has approved Ziihera (zanidatamab-hrii), a bispecific HER2-targeting antibody, as a first-line treatment for adults with unresectable locally advanced or metastatic HER2-positive gastroesophageal adenocarcinoma, triggering a US$250 million regulatory milestone payment from Jazz Pharmaceuticals to Zymeworks.
• This second FDA approval for zanidatamab in under two years further validates Zymeworks’ Azymetric bispecific antibody platform and strengthens its royalty- and milestone-based business model with potential for up to US$1.30 billion in additional milestones plus tiered royalties.
• Next, we’ll examine how this FDA approval and milestone payment could reshape Zymeworks’ investment narrative around its partnership-driven, capital-light model.

Invest in the nuclear renaissance through our list of 92 elite nuclear energy infrastructure plays powering the global AI revolution.

Zymeworks Investment Narrative Recap

To own Zymeworks, you need to believe its partnered, capital-light model can turn irregular milestones and royalties into a more durable revenue base. The new US$250 million Ziihera milestone and second FDA approval directly support that thesis in the near term, but the biggest risk remains the company’s dependence on partner execution and timing of future milestones to fund ongoing losses and R&D.

Among recent developments, the ongoing share repurchase program stands out. Having bought back about 5.9% of its shares for roughly US$60 million, Zymeworks has been using its balance sheet to reduce share count even while posting quarterly net losses. The Ziihera milestone meaningfully replenishes cash that had been allocated to buybacks, potentially giving the company more flexibility around future capital needs and partnership driven catalysts.

Yet, despite this approval, investors should still be aware that Zymeworks’ reliance on large, irregular milestones leaves it exposed if future payments arrive later than expected or...

Zymeworks' narrative projects $219.7 million revenue and $22.2 million earnings by 2029.

Uncover how Zymeworks' forecasts yield a $39.23 fair value, a 43% upside to its current price.

Exploring Other Perspectives

Before this approval, the most pessimistic analysts expected revenue of about US$155.1 million and only US$26.7 million in earnings by 2029, so if you lean toward that view, you are effectively bracing for slower royalty growth and lumpier milestone income than the consensus expects.

Explore 3 other fair value estimates on Zymeworks - why the stock might be worth over 6x more than the current price!

The Verdict Is Yours

Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

• A great starting point for your Zymeworks research is our analysis highlighting 2 key rewards that could impact your investment decision.
• Our free Zymeworks research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Zymeworks' overall financial health at a glance.

Seeking Other Investments?

Opportunities like this don't last. These are today's most promising picks. Check them out now:

• The future of work is here. Discover the 37 top robotics and automation stocks leading the charge in AI-driven automation and industrial transformation.
• Uncover the next big thing with 22 elite penny stocks that balance risk and reward.
• Find 49 companies with promising cash flow potential yet trading below their fair value.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.